Fundraising FoxEQT Life Sciences — 2024 Investments
9 investments dated 2024 · listed companies and verified rows first · show all
ATB Therapeutics is a biotech company developing bispecific antibody therapies and related immunological treatments.
BiotechHealthtechMedical Devices
Dr. Mark Throsby(Chief Executive Officer)
Co-investorsMRL Ventures FundV-Bio VenturesVIVES PartnersSambrinvestWallonie EntreprendreEQT
Vico Therapeutics develops targeted genetic medicines for neurological disorders, with a focus on antisense oligonucleotide therapies designed to address the underlying genetic causes of diseases like Huntington's disease and spinocerebellar ataxias.
AI & Machine LearningBiotechDeep TechHealthtechMedical Devices
Luc Dochez(Chair and Founder)inJosh Mandel-Brehm(Co-Founder)in
Co-investorsDroia VenturesKurma PartnersPureos BioventuresSeroba Life SciencesEurazeoIdinvest Partners+1 more
Evommune develops therapies targeting the underlying sources of chronic inflammatory diseases, aiming to provide underserved patient populations with more than symptomatic relief.
BiotechHealthtechPalo Alto, US
Luis Pena(President & Chief Executive Officer)inJanice Drew(Executive Officer)David Cohen(Director)Gregory Moss(Executive Officer)Eugene Bauer(Executive Officer, Director)Francois Beaubien(Director)
Board seatFelice Verduyn - Van Weegen· per SEC Form D · $115.5M raise · filed Jan 2025
Co-investorsAndera PartnersAvego BioScience CapitalB Capital GroupB4 CapitalBeiersdorf Innovation FundFemHealth Ventures+4 more
.jpeg){kind=logo}
Biotech
Co-investorsKurma PartnersSofinnova PartnersJohnson & Johnson Innovation – JJDCM VenturesSR One Capital Management
NUA Surgical develops surgical medical devices focused on maternal and infant health, currently in pre-clinical development.
FemTechHealthtechMedical DevicesGalway, IE
Barry(CEO & Founder)inMarie Therese(COO & Co-Founder)inPadraig(CTO & Co-Founder)
Co-investorsCatalytic Impact FoundationTMC Venture FundEnterprise Ireland
Phagenesis develops targeted pharyngeal electrical stimulation technology to treat neurogenic dysphagia by restoring neural pathways for safe swallowing.
Deep TechDigital HealthHealthtechMedical Devices
Co-investorsAphelion CapitalInnvotec Ltd.Northern GritstoneSectoral Asset Management
The page is a placeholder shell showing only cookie/consent notices for embedded third-party content (Vimeo, YouTube, reCAPTCHA, social media) and contains no substantive information about the company.
Dominik Schumacher(Founder)in
Co-investorsAndera PartnersAscenta CapitalBayern KapitalBioMedPartnerscoparionFrazier Life Sciences+7 more
VICO provides AI-generated forecasts and event risk ratings that track and triangulate analyst views into continuous time series data.
AI & Machine LearningData & InfrastructureFintech
Co-investorsAIN VenturesMultiball CapitalDroia VenturesEurazeoKurma PartnersPureos Bioventures
VICO is an online platform for finding verified furnished monthly housing — rooms, studios, and apartments — aimed at students, young professionals, and digital nomads relocating to a new city.
B2B MarketplacesConsumerMarketplacesPropTechTravel & HospitalityMedellín, CO
Manuel FranzinTilman Burfeindin
Co-investors500 GlobalDroia VenturesEurazeoKurma PartnersPureos Bioventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.